Cargando…

Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care

INTRODUCTION: Effective communication between patients and healthcare professionals (HCPs) is important to enhance outcomes in multiple sclerosis (MS). However, in practice, patients often report a disconnect in communication. Communication tools to aid patient–HCP communication have a long history...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oreja-Guevara, Celia, Potra, Stanca, Bauer, Birgit, Centonze, Diego, Giambastiani, Maria-Paz, Giovannoni, Gavin, Kesselring, Jürg, Langdon, Dawn, Morrow, Sarah A., Nouvet-Gire, Jocelyne, Pontaga, Maija, Rieckmann, Peter, Schippling, Sven, Alexandri, Nektaria, Shanahan, Jane, Thompson, Heidi, Van Galen, Pieter, Vermersch, Patrick, Yeandle, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822792/ https://www.ncbi.nlm.nih.gov/pubmed/31487006 http://dx.doi.org/10.1007/s12325-019-01071-9

Ejemplares similares

Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
por: Celius, Elisabeth G, et al.
Publicado: (2021)

Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
por: Vermersch, Patrick, et al.
Publicado: (2019)

Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
por: Yeandle, David, et al.
Publicado: (2018)

Caregiver Involvement in MS: Duty or Disruption?
por: Kesselring, Jürg, et al.
Publicado: (2021)

Summary of Research: Caregiver Involvement in MS: Duty or Disruption?
por: Kesselring, Jürg, et al.
Publicado: (2023)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)

Future MS care: a consensus statement of the MS in the 21st Century Steering Group
por: Rieckmann, Peter, et al.
Publicado: (2012)

What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation
por: Morrow, Sarah A., et al.
Publicado: (2023)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2023)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Résultats cliniques des patients atteints de la COVID-19 au cours des études de phase IV sur la cladribine comprimés dans le traitement de la sclérose en plaques
por: Karan, Radmila, et al.
Publicado: (2021)

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
por: Van Wijmeersch, Bart, et al.
Publicado: (2022)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
por: De Stefano, Nicola, et al.
Publicado: (2021)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Improving patient–physician dialog: commentary on the results of the MS Choices survey
por: Lugaresi, Alessandra, et al.
Publicado: (2012)

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
por: Pugliatti, Maura, et al.
Publicado: (2022)

Optical Coherence Tomography in Multiple Sclerosis and Neuromyelitis Optica: An Update
por: Noval, Susana, et al.
Publicado: (2011)

Shoulder Rotator Muscle Dynamometry Characteristics: Side Asymmetry and Correlations with Ball-Throwing Speed in Adolescent Handball Players
por: Pontaga, Inese, et al.
Publicado: (2014)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

From Provider to Enabler of Care? Reconfiguring Local Authority Support for Older People and Carers in Leeds, 2008 to 2013
por: Yeandle, Sue
Publicado: (2016)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Effects of Mobility-Enhancing Nursing Intervention in Patients with MS and Stroke: Randomised Controlled Trial
por: Imhof, Lorenz, et al.
Publicado: (2015)

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
por: Brochet, Bruno, et al.
Publicado: (2023)

Stochastic Properties of Discrete Waves of the Limulus Photoreceptor
por: Srebro, Richard, et al.
Publicado: (1970)

Independence of Location of Light Absorption and Discrete Wave Latency Distribution in Limulus Ventral Nerve Photoreceptors
por: Spiegler, J. B., et al.
Publicado: (1974)

Older Workers and Care-Giving in England: the Policy Context for Older Workers’ Employment Patterns
por: Yeandle, Sue, et al.
Publicado: (2017)

Clinically Isolated Syndromes Suggestive of Multiple Sclerosis: An Optical Coherence Tomography Study
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kqp8p915p9ig1qa9qqrhavqo3k